SUBSCRIPTION AGREEMENTAmending Agreement • June 9th, 2009 • Wex Pharmaceuticals Inc. • In vitro & in vivo diagnostic substances • British Columbia
The undersigned (the “Subscriber”) hereby agrees to purchase from the Corporation 16,327.272 common shares (the “Offered Shares”) of the Corporation for aggregate consideration of $4,489,999.80 (the “Subscription Price”), representing a subscription price of $0.275 per Offered Share and agrees to advance to the Corporation Cdn$l5,600,000 (the “Debenture Proceeds”) for a convertible debenture in the principal amount of Cdn$15,600,000 in the form attached as Schedule “A” (the “Convertible Debenture”), such advance to be in accordance with the terms of the Convertible Debenture, which Convertible Debenture will be convertible into common shares of the Corporation and pay interest by the issuance of common shares of the Corporation in accordance with the terms of the Convertible Debenture (together the “Debenture Shares” and together with the Convertible Debenture and the Offered Shares the “Securities”) on the terms and conditions set out in this subscription agreement (the “Subscription
